July 2026 QQ: VWD Therapeutic

We commemorate the 1926 publication by Finnish physician, Eric von Willebrand, Von Willebrand, E A (1926). “Hereditär pseudohemofili”. Finska Läkaresällskapets Handlingar (in Swedish). 68: 87–112. Dr. von Willebrand’s title, “Hereditary Pseudohemophilia,” was updated to our current name, von Willebrand disease, in the late 1930s, and the responsible protein was named von Willebrand factor in 1971. […]

Comments (0)

Bleeding Disorders

Jun 25 2026

george

June 2026 QQ Review: VWF Gain of Function

Our June 2026 QQ, which drew 30 responses, asked, “What VWD subtype is caused by a VWF gain of function?” Here are your responses: VWD type 1: 3 (10%) VWD subtype 2A: 1 (3%) VWD subtype 2B: 24 (80%) VWD subtype 2M: 2 (7%) VWD subtype 2N: 0 VWD type 1 is the quantitative form […]

Bleeding Disorders

A New Era in VWD Treatment

Click here for an informative LinkedIn/Hemostasis Today post from Shadi Tabibian, Deputy of Research at Blood Diseases Research Centers in Iran University of Medical Sciences, A New Era in VWD Treatment. For decades, the management of VWD has relied mainly on VWF concentrates, desmopressin, antifibrinolytic agents, and hormonal therapies. Although these treatments remain effective for […]

Bleeding Disorders

Review: Diagnosis and Management of Hemophilia A & B

Click here for an open-access review: Lim MY, Ardila J, Castaman G, et al. Diagnosis and management of hemophilia A and B. J Thromb Haemost. 2026;24:2341–54. doi: 10.1016/j.jtha.2026.04.005. PMID: 41967712. Abstract Hemophilia A and hemophilia B are inherited bleeding disorders caused by a deficiency or absence of coagulation factor FVIII and FIX, respectively. The severity […]

Bleeding Disorders

What is CAPS?

Here is an illustrated Hemostasis Today description by Dr. Abdul Mannan, Consultant Haematologist at Betsi Cadwaladr University Health Board, of catastrophic antiphospholipid syndrome (CAPS), which accounts for 1% of antiphospholipid syndrome (APS) diagnoses. As Dr. Mannan reports, the APL assay is a vital diagnostic consideration of this acute condition.

Lupus Anticoagulant

Coag Conversation: 100 Years of Von Willebrand Disease and Upcoming Advances

Click here for the first of our three-part Coag Conversation series, 100 Years of von Willebrand disease. featuring George Fritsma interviewing Robert Sidonio, MD. Dr. Sidonio is the Medical Director of the Clinical Research Office at the Aflac Cancer and Blood Disorders Center of Children’s Healthcare of Atlanta and is the Professor of Pediatrics, Emory […]

Bleeding Disorders

FXI Deficiency and LAC

Sacha Uljon, MD, PhD, Medical Director, Core Laboratory, Massachusetts General Hospital, sent this provocative question on 6-10-2026. Hello–just an update. This has been frustrating–others also have issues distinguishing FXI deficiency from LAC. Here is one report available from your medical library: Rabichow L, Dinh J, Nguyen L, Qiao J. In vitro differential inhibition of the […]

Blog

Emergency Hemorrhage Hemostasis Profile

Cristina Figueroa Villalba, MD, authored a provocative editorial, When minutes matter: the laboratory’s role in rapid hemostasis assessment in the May/June issue of CLN, a publication of ADLM. Please review this 10-minute read and respond with your recommendations for a rapid-test profile for acute hemorrhage. For instance, would you include a PTT, the DOASENSE® urinary […]

Bleeding Disorders

VTE in Sickle Cell Disease

Click this open-access 2026 article for a retrospective review of individuals with sickle cell disease to identify those who developed VTE. Bhasin N, Zhang L, Ajayi A, et al. Risk factors for venous thromboembolism in sickle cell disease. Res Pract Thromb Haemost. 2026;10(3):103454. doi: 10.1016/j.rpth.2026.103454. PMID: 42027307; PMCID: PMC13099461. Abstract Background: Individuals with sickle cell […]

Thrombophilia

Factor XIII and Clot Stability

Click here for an open-access illustrated discussion via Hemostasis Today by Abdul Mannan of the multiple roles of FXIII and the adverse effects of FXIII deficiency related to wound healing and clot integrity.

Comments (0)

Fibrinolysis

All Posts

July 2026 QQ: VWD Therapeutic

June 2026 QQ Review: VWF Gain of Function

A New Era in VWD Treatment

Review: Diagnosis and Management of Hemophilia A & B

What is CAPS?

Coag Conversation: 100 Years of Von Willebrand Disease and Upcoming Advances

FXI Deficiency and LAC

Emergency Hemorrhage Hemostasis Profile

VTE in Sickle Cell Disease

Factor XIII and Clot Stability

George Fritsma MS MLS

Cheat Sheets from George

Questions or Comments?

Quick Question